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Studying angiogenesis in three-dimensional 
ell cultures
Models of angiogenesis in vitro are based on the capacity of acti-
vated endothelial cells (cells forming the walls of blood vessels)
to invade three-dimensional substrates. These substrates (Matrix)
may consist of collagen gels, plasma clot, purified fibrin,
Matrigel, or a mixture of these proteins with others. It is possible
to embed and culture pieces of blood vessels (vascular explants
such as aortic rings) and to observe cells sprouting and forming
capillary-like structures (CLS) (Nicosia and Ottinetti, 1990).
These models allow the preservation of the vessel architecture
during the in vitro assay, and thus are close to an “ex vivo” model
(Kiefer et al., 2004). We have further developed the original
angiogenesis in vitro model for aortic explants by Roberto Nicosia
(Nicosia and Ottinetti, 1990), for the use with heart explants.
Briefly, pieces (ca. 1 mm3) of left ventricular myocardium of rat
or mouse hearts are embedded in a fibrin-gel, overlayed with
growth medium and angiogenic stimulants (agonists) and/or
inhibitors (antagonist). These cultures are then incubated for 7
days. Active molecules are added again every third day, and oxy-
gen saturation can be lowered down to 1% O2. A single mouse
heart allows assessing more than 20 different samples, each tested
in octuplicates. After 7 days CLS quantification is carried out by
visual scoring according to a scale that was defined by measuring
the area of capillary sprouts by morphometric software (Fig. 1).
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Formation of new blood vessels, a new therapeutic concept
Angiogenesis is a process of creating new capillaries to increase the blood supply within an organ or tissue. It occurs for
example in response to signals from an organ or tissue that is insufficiently oxygenated. In the heart, angiogenesis occurs in
response to acute or chronic blockages (occlusions) of coronary arteries. These occlusions induce a state of hypoxia known as
myocardial ischemia during angina pectoris or after a heart attack. In patients with coronary heart disease hypoxia and
myocardial ischemia often affect the function of the heart and results in a significant morbidity and mortality. Stimulation of
angiogenesis by pharmacological or molecular methods (therapeutic angiogenesis) would generate the formation of new
coronary collaterals in the myocardium, i.e., small branches of arteries and veins that newly develop to bypass narrowed or
blocked segments. Improving coronary collateral circulation would limit myocardial ischemia and is therefore a promising
new concept (Cao et al., 2005). 
Accordingly, substantial research resources are currently being invested into studying the therapeutic stimulation of
angiogenesis. Multiple animal studies and some preliminary human studies have confirmed the concept of stimulation of
collateral circulation by pharmacological or molecular methods. Current animal models of angiogenesis in vivo often use
complete blockage by ligation or a gradual reduction of blood flow in a major coronary artery to induce hypoxia-driven
angiogenesis. Many animals die due to myocardial infarction or cardiac rhythm disturbances during these – sometimes
cumbersome – surgical procedures. Furthermore, myocardial ischemia is often quite a painful condition for the animals.
http://3r-training.tierversuch.ch/en/module_3r/sensitization_in-vitro/acd
Background Information
Fig. 1: Three-dimensional angiogenesis assay in vitro.
During ex vivo culture of heart or aortic tissue in fibrin gels,
endothelial cells within the tissue are activated (by growth factors,
hypoxia), limited proteolysis of surrounding matrix occurs,
endothelial cells elongate, migrate and proliferate into the matrix
and attract pericytes to stabilise the nascent capillary tube.
Capillary tubes bifurcate and give rise to a primitive capillary tube-
network (A). After 7 days of incubation in 48 well plates, pieces of
heart are photographed digitally at 4X magnification (B). The total
surface of sprouts and the piece of heart is measured (C). The
fraction of heart and sprouts are set in relation to the total surface.
Example: surface of sprouts is 81356 µm2 (red colouring) and
surface of the heart is 152580 µm2 (yellow colouring); total surface
is 233936 µm2; thus sprouts are 35% of the total surface
corresponding to an angiogenic index of 4. 
Fig. 2: Differential morphology of CLS can be observed after
administration of different angiogenic molecules to mouse
heart explants: basic Fibroblast Growth Factor – bFGF (10
ng/ml), Platelet-Derived Growth Factor B-dimer -PDGF-BB (10
ng/ml), Vascular Endothelial Growth Factor – VEGF (5 ng/ml). 
A) In-gel characterization of CLS by FITC-coupled lectin G.
simplicifolia (green fluorescent) for endothelial cells and B)
magnification including Cy3-coupled anti alpha-smooth muscle
actin-staining (red staining) for smooth muscle cell. C) Confocal
micrograph of two crossing endothelial tubes. Tiny filpoodia reach
out and sense the environment for neighboring endothelial tubes.
COMPLETED PROJECTS
ALTEX 24, Special Issue 200736
Reproducibility of the in vitro system
First we tested basic culture conditions to ensure reproducibility
of the assay. In contrast to aortic explants forming CLS in
serum-free conditions, CLS formation of heart explants requires
fetal calf serum (5%) to ensure survival, whereas higher FCS
concentrations mask the activity of angiogenically active
molecules. In heart explants from mice younger than 8 weeks,
CLS formed spontaneously – an unwanted response for testing
the stimuli of angiogenic active factors. In 12-week-old adult
mice however, virtually no CLS was formed under normoxia
(standard culture condition, 20% O2). Sex of the animals did not
account for differences observed in CLS formation. Thus, for
our future experiments, we chose adult mice, older than 12
weeks, to abolish the effect of active angiogenesis during ado-
lescence of animals. Under hypoxia (1-3% O2) however, CLS
formation substantially increased, an established feature of
angiogenesis, observed in vivo and in vitro.
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Differential and in vivo like response toward
angiogenic factors
Different classic angiogenic molecules induced diverse CLS
patterns: Platelet Derived Growth Factor (PDGF-BB) induced
outgrowth of a mixture of organized branched endothelial
sprouts, unorganized single endothelial cells and pericytes/
smooth muscle cells. In contrast, basic Fibroblast Growth
Factor (ßFGF) induced mainly unbranched, elongated CLS.
Vascular Endothelial Growth Factor (VEGF165) induced elon-
gated CLS, and branching appeared complex (Fig. 2; ßFGF,
PDGF-BB, VEGF165). Independent of the morphology
induced by different agonists, outgrowing sprouts were com-
posed of endothelial cells by more than 90% when outgrowing
cells were subcultured and assessed by endothelial cell marker
CD31, Dil-Ac-LDL. Double in-gel-staining with FITC-cou-
pled lectin G. simplicifolia (green fluorescent) and Cy3-cou-
pled antibody against a-smooth muscle actin (red
fluorescence) revealed endothelial sprouts with single attached
smooth muscle cell-like cells (pericytes) (Fig. 2A-2C).
Pericyte attachment forming endothelial tubes have been
observed in vivo and contributes to vessel remodeling, matura-
tion and stabilisation. Also tiny filopodia, emerging from
endothelial sprouts, can be observed by confocal microscopy
(Fig. 2C). These filopodia sense neighbouring endothelial
tubes and potentially guide network formation.
Fig. 3A: In vitro angiogenesis of the heart is abrogated under
hypoxia in iNOS (–/–) mice. 
In vitro angiogenesis of aortas (blue columns) and hearts (green
columns) 7 days after addition of growth regulatory molecules:
platelet-derived growth factor (PDGF)-BB (10 ng/ml), fibroblast
growth factor (bFGF) (10 ng/ml) and vascular endothelial growth
factor (VEGF)164 (5 ng/ml).
A standardized scale ranging from 0 to 6 indicates the degree of
sprouting (angiogenic index). Data points given represent the mean
of three experiments ± SEM. Ø – Sprouting undetectable; iNOS –
inducible nitric oxide synthases.
Fig. 3B: Ang II induces dose-dependent sprouting in vitro in
adult mouse hearts in hypoxia. 
Pieces of mouse heart were stimulated with Ang II (blue graph) or
AT2 agonist CGP-42112 (green graph) from 10-10 to 10-6 mol/L
and incubated under hypoxia for 7 days. Data points represent the
mean of 5 independent experiments. C. Ang II–induced
angiogenesis is impaired in hearts from AT2-/- but not from AT1-/-
mouse. Pieces of mouse heart from AT2-/- (blue columns) 
and AT1-/- mice (green columns) were stimulated with Ang II 
(10-7 mol/l) alone or in combination with AT1 blocker losartan 
(Los; 10-6 mol/l) and incubated under hypoxia for 7 days.
VEGF164 (10 ng/ml) was used as a positive control. Data points
represent the mean of 5 independent experiments. 
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Nitric oxide as inducer of angiogenesis 
(Munk et al., 2006)
Nitric oxide (NO) promotes not only blood vessel relaxation and
regulates vascular tone, but is critical for angiogenesis initiation
and modulation (Sieber et al., 2001; Sumanovski et al., 1999). In
this study we have investigated whether inducible NO synthase
(iNOS) is required for angiogenesis in vitro of the heart versus
angiogenesis originating from aorta..
We found that in vitro angiogenesis of the heart in mice lack-
ing the iNOS gene (iNOS–/–) under hypoxia was totally abro-
gated and endothelial sprout formation could not be restored
with classic angiogenic growth factors (Fig. 3A). In contrast, in
vitro angiogenesis in aortas was still present, albeit reduced and
without a response to angiogenic growth factors (Fig. 3A).
Thus, our results suggests that angiogenesis is regulated in an
organ specific way and requires iNOS on the heart. iNOS-inde-
pendent pathways may exist that can regulate angiogenesis in
aorta and that are not present or less active in the hypoxic heart.
This supports the need of organ specific models for angiogene-
sis and the concept that the angiogenic response in adult hypoxic
hearts is far more restricted than in other organs.
Vasoactive peptides and their role in angiogenesis
(Munk et al., 2007)
The vasoactive peptide Angiotensin II (Ang II) is a key regula-
tor of blood pressure. Most of the Ang II cardiovascular effects,
for example, vasoconstriction, are attributed to Angiotensin
II’sAT1 receptor. AT1 is ubiquitously expressed, whereas the
AT2 receptor is upregulated in response to ischemia and inflam-
mation. Previous studies have shown that the AT2 receptor may
interact with the bradykinin receptor, the B2 kinin receptor
(BK2), during signaling. We have therefore investigated the
mechanism of heart angiogenesis in response to Ang II under
conditions of normoxia and severe hypoxia by dissecting the
role of AT and BK receptor subtypes using the model of angio-
genesis in vitro. We found that Ang II and AT2 receptor agonists
dose-dependently induce angiogenesis in vitro of the heart and
requires hypoxic conditions (Fig. 3B). However, Ang II was not
angiogenic in mice hearts lacking AT2 receptor or, interestingly,
the BK2 receptor, whereas no impairment of angiogenesis was
observed in hearts from AT1-/- mice (Fig. 3C). We could cor-
roborate these findings when using specific pharmacological
antagonist against AT1, AT2, BK1 and BK2 receptors. We con-
cluded that angiogenesis induced by Ang II requires signaling
through the AT2 receptor and is mediated by an increase in BK
production and activation of the BK2 receptor. Currently, we are
using the assay to assess mechanisms of BK2-dependent angio-
genesis.
A versatile in vitro model
Thus, a wide range of questions connected with therapeutic
angiogenesis can be answered without the use of in vivo experi-
ments: (1) Induction and repression of early to midterm mor-
phogenic steps in angiogenesis can be investigated in mouse and
rat hearts. (2) Pharmacological compounds can rapidly be
screened using only a small number of animals. (3) Assays can
be performed under controlled experimental conditions, such as
under a distinct oxygen saturation. (4) The role of specific genes
in heart angiogenesis can be investigated by using tissue from
knockout mice. 
The assay has gained attention by other research laboratories,
particularly because of the possibility to use capillary sprouts for
in vitro immunolocalization of proteins (Fig. 2).
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